The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
Abstract
PURPOSE: To review recent advances in peripheral-blood progenitor-cell (PBPC) transplantation in order to define the optimal cell dose required for autologous and allogeneic transplantation. MATERIALS AND METHODS: A search of MEDLINE was conducted to identify relevant publications. Their bibliographies were also used to identify further articles and abstracts for critical review. RESULTS: The CD34+ cell content of a graft is regarded as an accurate predictor of engraftment success. Postchemotherapy autologous PBPC transplantation with ≥ 5 × 10 6 CD34+ cells/kg body weight leads to more rapid engraftment than does transplantation of lower cell doses. Further increases in transplant cell dose further accelerate platelet but not neutrophil engraftment. Evidence that long-term hematopoietic recovery may be more accurately predicted by the subpopulation of primitive progenitors transplanted suggests that the content of CD34+CD33− and long-term culture-initiating cells in cell collection samples may be important for predicting successful engraftment, particularly in patients with poor mobilization. Allogeneic transplantation has been limited by concerns regarding graft-versus-host disease and the use of hematopoietic growth factors in donors. The risk of graft rejection and engraftment failure after HLA-mismatched allogeneic transplantation may be overcome by intensive chemoradiotherapy and the infusion of large numbers of T cell–depleted hematopoietic stem cells. CONCLUSION: An optimal cell dose of ≥ 8 × 10 6 CD34+ cells/kg seems to be recommended for autologous PBPC transplantation. This dose facilitates the administration of scheduled chemotherapy on time and reduces the demand for other supportive therapies. A combination of growth factors may enable patients with poor mobilization to achieve a collection sufficient to allow transplantation. The optimum PBPC dose for allogeneic transplantation remains to be defined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metcalf, D. (1989) · Nature · doi:10.1038/339027a0 · Cited by 1,023
Cited by
Pedrazzoli, P., Ledermann, J. A., Lotz, J.-P., Leyvraz, S., Aglietta, M., Rosti, G., Champion, K. M., Secondino, S., Selle, F., Ketterer, N., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl044 · Cited by 655
Self-citationFlomenberg, N. (2005) · Blood · doi:10.1182/blood-2005-02-0468 · Cited by 460
Devine, S. M., Flomenberg, N., Vesole, D. H., Liesveld, J., Weisdorf, D., Badel, K., Calandra, G., & DiPersio, J. F. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.131 · Cited by 368
Pusic, I., Jiang, S. Y., Landua, S., Uy, G. L., Rettig, M. P., Cashen, A. F., Westervelt, P., Vij, R., Abboud, C. N., Stockerl-Goldstein, K. E., et al. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.07.004 · Cited by 352
Plouffe, B. D., Mahalanabis, M., Lewis, L. H., Klapperich, C. M., & Murthy, S. K. (2012) · Analytical Chemistry · doi:10.1021/ac2022844 · Cited by 96
Metadata
- Authors
- Siena, S., Schiavo, R., Pedrazzoli, P., & Carlo-Stella, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-03-13
- Volume
- 18
- Issue
- 6
- Pages
- 1360-1377
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2248611751
- Cited by
- 312
- References
- 1
- FWCI
- 10.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy. https://app.cochat.ai/papers/10.1200/jco.2000.18.6.1360
- The paper
- Siena, S., Schiavo, R., Pedrazzoli, P., & Carlo-Stella, C. (2000). Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.6.1360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.